ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 152 filers reported holding ARRAY BIOPHARMA INC in Q2 2015. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $5,937,000 | +47.7% | 675,469 | +13.4% | 0.01% | +40.0% |
Q3 2016 | $4,019,000 | +90.7% | 595,435 | +0.6% | 0.01% | +66.7% |
Q2 2016 | $2,107,000 | +46.5% | 591,989 | +21.4% | 0.00% | +50.0% |
Q1 2016 | $1,438,000 | -29.0% | 487,467 | +1.6% | 0.00% | -33.3% |
Q4 2015 | $2,024,000 | -7.5% | 479,611 | -0.0% | 0.00% | 0.0% |
Q3 2015 | $2,187,000 | -37.7% | 479,668 | -1.5% | 0.00% | -25.0% |
Q2 2015 | $3,512,000 | +13.9% | 487,155 | +16.5% | 0.00% | 0.0% |
Q1 2015 | $3,083,000 | +75.3% | 418,251 | +12.5% | 0.00% | +100.0% |
Q4 2014 | $1,759,000 | +30.0% | 371,942 | -1.9% | 0.00% | 0.0% |
Q3 2014 | $1,353,000 | -21.2% | 379,016 | +0.7% | 0.00% | 0.0% |
Q2 2014 | $1,717,000 | +6.5% | 376,494 | +9.7% | 0.00% | 0.0% |
Q1 2014 | $1,612,000 | -4.7% | 343,080 | +1.6% | 0.00% | -33.3% |
Q4 2013 | $1,692,000 | -17.8% | 337,804 | +2.1% | 0.00% | 0.0% |
Q3 2013 | $2,059,000 | +45.9% | 331,004 | +6.5% | 0.00% | 0.0% |
Q2 2013 | $1,411,000 | – | 310,691 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Redmile Group, LLC | 17,850,650 | $75,330,000 | 5.64% |
BVF INC/IL | 6,682,711 | $28,201,000 | 4.81% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 8,729,361 | $36,838,000 | 1.49% |
First Light Asset Management, LLC | 530,391 | $2,238,000 | 0.94% |
KOPP INVESTMENT ADVISORS LLC | 376,477 | $1,589,000 | 0.78% |
Sarissa Capital Management LP | 700,000 | $2,954,000 | 0.57% |
Orbimed Advisors | 10,689,000 | $45,108,000 | 0.41% |
Bedell Frazier Investment Counselling, LLC | 178,971 | $755,000 | 0.37% |
PINNACLE ASSOCIATES LTD | 3,453,487 | $14,574,000 | 0.31% |
Artal Group S.A. | 3,710,000 | $15,656,000 | 0.29% |